STAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trial
Phase 3positiveTrutaknaPositive
AI Analysis
Summary
Vera Therapeutics' Trutakna demonstrated strong efficacy in a Phase 3 trial for IgAN, stabilizing kidney function and reducing mortality risk. The positive results represent a significant advancement in the treatment of this kidney disease.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Stabilized kidney function and reduced risk of death and other complications in IgAN patients
Importance:8/10
Sentiment:
0.85
Phase 3kidney diseaseIgANpositive dataclinical trial
Related Companies
Read the original article
Published by STAT News on September 15, 2026 10:30 AM